Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $2.1 million.

  • ImmunityBio's Other Accumulated Expenses rose 4992.92% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 4992.92%. This contributed to the annual value of $1.0 million for FY2024, which is 4664.8% up from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Other Accumulated Expenses is $2.1 million, which was up 4992.92% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Other Accumulated Expenses registered a high of $2.9 million during Q1 2022, and its lowest value of $556000.0 during Q1 2024.
  • Its 5-year average for Other Accumulated Expenses is $1.5 million, with a median of $1.4 million in 2024.
  • Per our database at Business Quant, ImmunityBio's Other Accumulated Expenses crashed by 7416.27% in 2021 and then soared by 37679.86% in 2025.
  • Quarter analysis of 5 years shows ImmunityBio's Other Accumulated Expenses stood at $2.6 million in 2021, then crashed by 37.26% to $1.6 million in 2022, then plummeted by 56.02% to $716000.0 in 2023, then skyrocketed by 46.65% to $1.0 million in 2024, then soared by 101.62% to $2.1 million in 2025.
  • Its Other Accumulated Expenses was $2.1 million in Q3 2025, compared to $1.9 million in Q2 2025 and $2.7 million in Q1 2025.